Pain Management · OpioidRegulatory Approvalregulatorymid-term

FDA Approves Supplemental NDA for NUCYNTA (Tapentadol Hydrochloride)

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Collegium Pharma7 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/29/2026, 6:32:56 AM

Assessment confidence: 52% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's approval of a supplemental NDA for NUCYNTA marks a significant regulatory development that could strengthen Collegium Pharma's competitive position in the pain management sector. This approval necessitates a reassessment of market strategies among competitors in the opioid space. Regulatory context from FDA (FDA AP — NUCYNTA (SUPPL)) supports the near-term read. Assessment grounded in 14 ranked evidence items (3 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this approval on market share and competitive strategies in pain management. The strongest clinical anchor is Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain (ClinicalTrials.gov), sub-indication match (pain). In pain, 8 regulatory and 2 competitive items passed relevance filtering for Collegium Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc (Humanexa Signals) — sub-indication match (pain). Secondary pressure from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. This approval may enhance Collegium Pharma's position in the pain management market, potentially impacting competitors in the opioid space.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — NUCYNTA (SUPPL) (FDA). Entity match (nucynta); Regulatory pathway relevance (nda). This supplemental approval could lead to further labeling changes or new indications, which may influence compliance and marketing strategies for NUCYNTA.

Key Risks

Elevated medium regulatory exposure for Collegium Pharma could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

The approval may lead to increased market share for NUCYNTA, affecting revenue projections for both Collegium Pharma and its competitors in the opioid market.
Portfolio teams should assess the implications of this approval on market share and competitive strategies in pain management.

What Would Change This Assessment

This becomes more urgent if Monitor for any additional labeling changes or new indications that may arise from this supplemental approval.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — NUCYNTA (SUPPL)
FDAmedium relevance
Entity match (nucynta); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — NUCYNTA ER (SUPPL)
FDAmedium relevance
Entity match (nucynta); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — NUCYNTA (SUPPL)
FDAmedium relevance
Entity match (nucynta); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — NUCYNTA (SUPPL)
FDAmedium relevance
Entity match (nucynta); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — NUCYNTA ER (SUPPL)
FDAmedium relevance
Entity match (nucynta); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source

Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Pelvic Pain in Women With Endometriosis
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Study Title: A Multicenter, Prospective, Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc
Humanexa Signalsmedium relevance
Sub-indication match (pain)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Collegium Pharma
NUCYNTA
opioid market competitors

Commercial impact

medium

The approval may lead to increased market share for NUCYNTA, affecting revenue projections for both Collegium Pharma and its competitors in the opioid market.

Regulatory impact

medium

This supplemental approval could lead to further labeling changes or new indications, which may influence compliance and marketing strategies for NUCYNTA.

What to watch

Monitor for any additional labeling changes or new indications that may arise from this supplemental approval.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.